Lung cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lung cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-drug-combination-with-pembrolizumab-guided-by-blood-biomarkers-for-patients-with-metastatic-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:08:50 +0000 https://clinicaltrials.eu/trial/study-of-drug-combination-with-pembrolizumab-guided-by-blood-biomarkers-for-patients-with-metastatic-non-small-cell-lung-cancer/ This study is looking at metastatic non-small cell lung cancer, which is an advanced form of lung cancer that has spread to other parts of the body. The study will use several different medications to treat this condition. One treatment option is pembrolizumab, which is a type of immunotherapy that helps the body’s immune system fight cancer cells. Other medications that may be used in combination include chemotherapy drugs such as Abraxane (which contains paclitaxel albumin-bound), paclitaxel, cisplatin, carboplatin, and pemetrexed. These chemotherapy drugs work by stopping cancer cells from growing and dividing. The purpose of this study is to find out whether adding chemotherapy to immunotherapy treatment improves how long patients live without their cancer getting worse and their overall survival time, based on a blood test that measures cancer markers called circulating tumor DNA.

Patients entering this study must have already started treatment with pembrolizumab for their advanced lung cancer and received at least one or two cycles of this medication. Before joining the study, patients will have a special blood test that looks for circulating tumor DNA, which are small pieces of cancer genetic material that can be found in the blood. This blood test helps doctors understand how the cancer is responding to treatment. Patients will also have imaging scans such as computed tomography of the chest, abdomen, and pelvis, and possibly brain scans to check all areas where cancer may be present. These tests must show that the cancer is stable or responding to treatment, not rapidly getting worse.

Once enrolled in the study, patients will be randomly assigned to continue receiving pembrolizumab alone or to receive pembrolizumab combined with chemotherapy. The chemotherapy combinations may vary depending on the specific type of lung cancer cells. Treatment will continue for up to twelve months for chemotherapy and up to twenty-four months for pembrolizumab, depending on how well the treatment works and how the patient tolerates it. Throughout the study, doctors will monitor patients closely with regular blood tests and imaging scans to see how well the treatment is working and to check for any side effects.

]]> Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-pembrolizumab-in-adults-with-advanced-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:28:52 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-pembrolizumab-in-adults-with-advanced-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC). The study is exploring a new treatment approach using a personalized therapy called ATL001, which is a type of cell therapy. This therapy is designed to target specific mutations found in cancer cells. The study will also look at how ATL001 works when used alone and in combination with another medication called pembrolizumab, which is already used in cancer treatment.

The main goal of the study is to assess the safety and how well patients tolerate ATL001 as a treatment. Participants in the study will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will monitor patients over time to see how their cancer responds to the treatment and to check for any side effects. The study will also compare the effects of the treatment with those of a placebo.

Throughout the study, patients will have regular check-ups to track their health and the progress of their cancer. The study will measure changes in tumor size and overall health outcomes, such as how long patients live without their cancer getting worse. This research aims to provide new insights into treating non-small cell lung cancer and potentially offer new options for patients with this type of cancer.

]]>